Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries
Authors:
- Enrico CostaECEnrico Costa
- Silvia GirottiSGSilvia Girotti
- Saif ElayanSESaif Elayan
- Carlo CastellaniCCCarlo Castellani
- Maria Cavaller BellaubiMBMaria Cavaller Bellaubi
- Wim GoettschWGWim Goettsch
- Momir RadulovićMRMomir Radulović
- João RochaJRJoão Rocha
- Pierluigi RussoPRPierluigi Russo
- Steven SimoensSSSteven Simoens
- Christine LeopoldCLChristine Leopold
Open Access
- 21 July 2026
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Recommended methods for the collection of clinical expert judgment in rare diseases: Generating evidence to support reimbursement of orphan drugsInternational Journal of Technology Assessment in Health Care, 2025
- Costs prohibiting access to cystic fibrosis drugThe Lancet, 2025
- Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines listJournal of Cystic Fibrosis, 2025
- Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European UnionJournal of Cystic Fibrosis, 2024
- Traits, trends and hits of orphan drug designations in cystic fibrosisJournal of Cystic Fibrosis, 2023
- Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countriesESMO Open, 2023
- Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?Value in Health, 2022
- Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic FibrosisJournal of Cystic Fibrosis, 2021
- Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating MutationValue in Health, 2020
- The future of cystic fibrosis care: a global perspectiveThe Lancet Respiratory Medicine, 2020